Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,502 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-101) | completed | Phase 3 | 547 | AmgenINDUSTRY | 37 | May 27, 2026 | clinicaltrials |
| NCT05668988 | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) | active not recruiting | Phase 3 | 324 | Dizal PharmaceuticalsINDUSTRY | 15 | May 26, 2026 |
| clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT02799706 | Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer(PEGASUS) | active not recruiting | Phase 3 | 885 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | May 22, 2026 | clinicaltrials |
| NCT04628494 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)(EPCORE DLBCL-1) | active not recruiting | Phase 3 | 483 | GenmabINDUSTRY | 24 | May 22, 2026 | clinicaltrials |
| NCT01376752 | Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment(CHIPOR) | active not recruiting | Phase 3 | 415 | UNICANCEROTHER | 3 | May 20, 2026 | clinicaltrials |
| NCT05615818 | Personalized Medicine for Advanced Biliary Cancer Patients(SAFIR-ABC10) | recruiting | Phase 3 | 800 | UNICANCEROTHER | 3 | May 19, 2026 | clinicaltrials |
| NCT06760637 | Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease(FourLight-3) | active not recruiting | Phase 3 | 1,035 | PfizerINDUSTRY | 30 | May 19, 2026 | clinicaltrials |
| NCT04154956 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients(CARMEN-LC03) | terminated | Phase 3 | 389 | SanofiINDUSTRY | 26 | May 18, 2026 | clinicaltrials |
| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | recruiting | Phase 3 | 1,180 | Celcuity IncINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT04622319 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | active not recruiting | Phase 3 | 1,600 | Daiichi SankyoINDUSTRY | 31 | May 15, 2026 | clinicaltrials |
| NCT05374512 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | active not recruiting | Phase 3 | 644 | AstraZenecaINDUSTRY | 23 | May 15, 2026 | clinicaltrials |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | active not recruiting | Phase 3 | 707 | AmgenINDUSTRY | 22 | May 15, 2026 | clinicaltrials |
| NCT05566795 | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | active not recruiting | Phase 3 | 418 | Day One Biopharmaceuticals, Inc.INDUSTRY | 30 | May 14, 2026 | clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT03017326 | Paediatric Hepatic International Tumour Trial(PHITT) | active not recruiting | Phase 3 | 450 | University of BirminghamOTHER | 14 | May 13, 2026 | clinicaltrials |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | active not recruiting | Phase 3 | 165 | AbbVieINDUSTRY | 23 | May 13, 2026 | clinicaltrials |
| NCT04550260 | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC(KUNLUN) | active not recruiting | Phase 3 | 640 | AstraZenecaINDUSTRY | 16 | May 13, 2026 | clinicaltrials |
| NCT05918302 | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.(LEVEL) | recruiting | Phase 3 | 170 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | May 12, 2026 | clinicaltrials |
| NCT04987203 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | completed | Phase 3 | 343 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | May 8, 2026 | clinicaltrials |
| NCT06295731 | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC(HexAgon-HN) | active not recruiting | Phase 2 / Phase 3 | 410 | Inhibrx Biosciences, IncINDUSTRY | 13 | May 8, 2026 | clinicaltrials |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)(INTerpath-007) | terminated | Phase 2 / Phase 3 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 20 | May 8, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)(EVOKE-01) | active not recruiting | Phase 3 | 603 | Gilead SciencesINDUSTRY | 20 | May 7, 2026 | clinicaltrials |
| NCT02446444 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer(ENZARAD) | active not recruiting | Phase 3 | 802 | University of SydneyOTHER | 9 | May 6, 2026 | clinicaltrials |
| NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma(LBL 2018) | recruiting | Phase 3 | 683 | University Hospital MuensterOTHER | 21 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | active not recruiting | Phase 3 | 747 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 5, 2026 | clinicaltrials |
| NCT05173987 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | active not recruiting | Phase 3 | 280 | Merck Sharp & Dohme LLCINDUSTRY | 27 | May 5, 2026 | clinicaltrials |
| NCT03319667 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant(IMROZ) | active not recruiting | Phase 3 | 475 | SanofiINDUSTRY | 21 | May 4, 2026 | clinicaltrials |
| NCT03504397 | A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.(Spotlight) | active not recruiting | Phase 3 | 565 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | May 4, 2026 | clinicaltrials |
| NCT03711032 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | active not recruiting | Phase 3 | 1,397 | Merck Sharp & Dohme LLCINDUSTRY | 30 | May 1, 2026 | clinicaltrials |
| NCT04305496 | Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer(CAPItello-291) | active not recruiting | Phase 3 | 818 | AstraZenecaINDUSTRY | 19 | Apr 30, 2026 | clinicaltrials |
| NCT04608318 | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)(CLL17) | active not recruiting | Phase 3 | 897 | German CLL Study GroupOTHER | 13 | Apr 30, 2026 | clinicaltrials |
| NCT07558083 | FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients(FOLICOLOR) | recruiting | Phase 3 | 150 | University Hospital, AntwerpOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06117774 | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)(DeLLphi-306) | active not recruiting | Phase 3 | 404 | AmgenINDUSTRY | 27 | Apr 29, 2026 | clinicaltrials |
| NCT04261777 | Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients | terminated | Phase 3 | 172 | Saving Patients' Lives Medical B.V.INDUSTRY | 4 | Apr 28, 2026 | clinicaltrials |
| NCT04384484 | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(LOTIS 5) | active not recruiting | Phase 3 | 440 | ADC Therapeutics S.A.INDUSTRY | 21 | Apr 28, 2026 | clinicaltrials |
| NCT04916613 | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)(GETUG-AFU 40) | recruiting | Phase 3 | 300 | UNICANCEROTHER | 12 | Apr 28, 2026 | clinicaltrials |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer(monarchE) | active not recruiting | Phase 3 | 5,637 | Eli Lilly and CompanyINDUSTRY | 38 | Apr 24, 2026 | clinicaltrials |
| NCT04666038 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN CLL-321) | active not recruiting | Phase 3 | 238 | Loxo Oncology, Inc.INDUSTRY | 24 | Apr 24, 2026 | clinicaltrials |
| NCT03593018 | Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL | completed | Phase 3 | 86 | The Lymphoma Academic Research OrganisationOTHER | 5 | Apr 23, 2026 | clinicaltrials |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma(DREAMM 7) | active not recruiting | Phase 3 | 494 | GlaxoSmithKlineINDUSTRY | 13 | Apr 23, 2026 | clinicaltrials |
| NCT05374590 | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis(ADAPT Jr +) | enrolling by invitation | Phase 2 / Phase 3 | 12 | argenxINDUSTRY | 10 | Apr 23, 2026 | clinicaltrials |
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer(SASCIA) | active not recruiting | Phase 3 | 1,332 | GBG Forschungs GmbHOTHER | 7 | Apr 22, 2026 | clinicaltrials |
| NCT05352672 | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | active not recruiting | Phase 3 | 1,546 | Regeneron PharmaceuticalsINDUSTRY | 24 | Apr 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials